Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Leukemia

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 49 articles: HTML format

Single Articles

July 2021
1. GOTO H, Yoshino Y, Ito M, Nagai J, et al
   Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2021 Jul 18. pii: 10.1007/s00280-021-04321.
   PubMed    
   
   
   June 2021
2. TOKSVANG LN, Andres-Jensen L, Rank CU, Niinimaki R, et al
   Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
   Cancer Chemother Pharmacol. 2021 Jun 18. pii: 10.1007/s00280-021-04316.
   PubMed     Abstract available
   
   
   May 2021
3. YOUSSEF YH, Makkeyah SM, Soliman AF, Meky NH, et al
   Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2021 May 7. pii: 10.1007/s00280-021-04290.
   PubMed     Abstract available
   
   
   April 2021
4. NIELSEN SN, Toksvang LN, Grell K, Nersting J, et al
   No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
   Cancer Chemother Pharmacol. 2021 Apr 29. pii: 10.1007/s00280-021-04281.
   PubMed     Abstract available
   
   
   March 2021
5. LARSEN RH, Hjalgrim LL, Degn M, Nersting J, et al
   Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2021 Mar 23. pii: 10.1007/s00280-020-04219.
   PubMed     Abstract available
   
   
   
6. KASHANIAN SM, Holtzman NG, Patzke CL, Cornu J, et al
   Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
   Cancer Chemother Pharmacol. 2021 Mar 7. pii: 10.1007/s00280-021-04252.
   PubMed     Abstract available
   
   
   January 2021
7. KANG D, Ludwig E, Jaworowicz D, Huang H, et al
   Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia.
   Cancer Chemother Pharmacol. 2021 Jan 8. pii: 10.1007/s00280-020-04204.
   PubMed     Abstract available
   
   
   November 2020
8. AL-SHEIKH A, Yousef AM, Alshamaseen D, Farhad R, et al
   Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2020 Nov 10. pii: 10.1007/s00280-020-04197.
   PubMed     Abstract available
   
   
   October 2020
9. LATOCH E, Kononczuk K, Taranta-Janusz K, Muszynska-Roslan K, et al
   Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.
   Cancer Chemother Pharmacol. 2020 Oct 14. pii: 10.1007/s00280-020-04164.
   PubMed     Abstract available
   
   
   September 2020
10. ABBARA C, Drevin G, Ferec S, Ghamrawi S, et al
    Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples.
    Cancer Chemother Pharmacol. 2020 Sep 29. pii: 10.1007/s00280-020-04150.
    PubMed     Abstract available
    
    
    
11. PRAKASH C, Fan B, Ke A, Le K, et al
    Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2020 Sep 25. pii: 10.1007/s00280-020-04148.
    PubMed     Abstract available
    
    
    
12. LIN S, Shaik N, Chan G, Cortes JE, et al
    An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
    Cancer Chemother Pharmacol. 2020 Sep 3. pii: 10.1007/s00280-020-04132.
    PubMed     Abstract available
    
    
    
13. LUCAFO M, Sicari D, Chicco A, Curci D, et al
    miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.
    Cancer Chemother Pharmacol. 2020;86:361-374.
    PubMed     Abstract available
    
    
    August 2020
14. ELMELIEGY M, Den Haese J, Talati C, Wetzler M, et al
    Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2020 Aug 3. pii: 10.1007/s00280-020-04114.
    PubMed     Abstract available
    
    
    July 2020
15. ZHANG H, Xu H, Zhang R, Zhao X, et al
    Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-kappaB inhibition in acute myeloid leukemia cells.
    Cancer Chemother Pharmacol. 2020 Jul 21. pii: 10.1007/s00280-020-04115.
    PubMed     Abstract available
    
    
    June 2020
16. LARSEN RH, Hjalgrim LL, Grell K, Kristensen K, et al
    Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2020 Jun 9. pii: 10.1007/s00280-020-04097.
    PubMed     Abstract available
    
    
    May 2020
17. FAN B, Dai D, DiNardo CD, Stein E, et al
    Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Cancer Chemother Pharmacol. 2020;85:959-968.
    PubMed     Abstract available
    
    
    April 2020
18. LIU X, Jiang Y, Nowak B, Ichikawa S, et al
    Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination.
    Cancer Chemother Pharmacol. 2020;85:661-672.
    PubMed     Abstract available
    
    
    March 2020
19. GOTO H, Yoshino Y, Ito M, Nagai J, et al
    Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2020 Mar 6. pii: 10.1007/s00280-020-04045.
    PubMed     Abstract available
    
    
    January 2020
20. OKABE S, Tanaka Y, Moriyama M, Gotoh A, et al
    Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
    Cancer Chemother Pharmacol. 2020 Jan 4. pii: 10.1007/s00280-019-04022.
    PubMed     Abstract available
    
    
    November 2019
21. LI H, Xu Q, Wang Y, Chen K, et al
    Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2019 Nov 1. pii: 10.1007/s00280-019-03980.
    PubMed     Abstract available
    
    
    October 2019
22. MEDELLIN-GARIBAY SE, Hernandez-Villa N, Correa-Gonzalez LC, Morales-Barragan MN, et al
    Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2019 Oct 31. pii: 10.1007/s00280-019-03977.
    PubMed     Abstract available
    
    
    
23. XIA F, Ma S, Bian Y, Yu D, et al
    A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2019 Oct 25. pii: 10.1007/s00280-019-03973.
    PubMed     Abstract available
    
    
    July 2019
24. LIN TL, Newell LF, Stuart RK, Michaelis LC, et al
    A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
    Cancer Chemother Pharmacol. 2019;84:163-173.
    PubMed     Abstract available
    
    
    June 2019
25. ADIGE S, Lapidus RG, Carter-Cooper BA, Duffy A, et al
    Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
    Cancer Chemother Pharmacol. 2019;83:1105-1112.
    PubMed     Abstract available
    
    
    
26. FAROOQ MU, Mushtaq F, Farooq A, Khan DH, et al
    FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
    Cancer Chemother Pharmacol. 2019;83:1191-1193.
    PubMed     Abstract available
    
    
    May 2019
27. NOBRE CF, Newman MJ, DeLisa A, Newman P, et al
    Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
    Cancer Chemother Pharmacol. 2019 May 27. pii: 10.1007/s00280-019-03875.
    PubMed     Abstract available
    
    
    
28. LEI M, Liu L, Wu D
    Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro.
    Cancer Chemother Pharmacol. 2019 May 21. pii: 10.1007/s00280-019-03857.
    PubMed     Abstract available
    
    
    February 2019
29. NAUSHAD SM, Dorababu P, Rupasree Y, Pavani A, et al
    Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2019 Feb 26. pii: 10.1007/s00280-019-03803.
    PubMed     Abstract available
    
    
    
30. SINGH R, Mehrotra S, Gopalakrishnan M, Gojo I, et al
    Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
    Cancer Chemother Pharmacol. 2019;83:319-328.
    PubMed     Abstract available
    
    
    January 2019
31. YOUSEF AM, Farhad R, Alshamaseen D, Alsheikh A, et al
    Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2019 Jan 25. pii: 10.1007/s00280-019-03776.
    PubMed     Abstract available
    
    
    November 2018
32. FOSTER JH, Thompson PA, Bernhardt MB, Margolin JF, et al
    A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
    Cancer Chemother Pharmacol. 2018 Nov 28. pii: 10.1007/s00280-018-3733.
    PubMed     Abstract available
    
    
    
33. KHERA S, Trehan A, Bhatia P, Singh M, et al
    Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2018 Nov 24. pii: 10.1007/s00280-018-3732.
    PubMed     Abstract available
    
    
    October 2018
34. NERSTING J, Nielsen SN, Grell K, Paerregaard M, et al
    Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
    Cancer Chemother Pharmacol. 2018 Oct 15. pii: 10.1007/s00280-018-3704.
    PubMed     Abstract available
    
    
    May 2018
35. GAO C, Hu S, Guo M, Hai X, et al
    Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
    Cancer Chemother Pharmacol. 2018 May 29. pii: 10.1007/s00280-018-3606.
    PubMed     Abstract available
    
    
    March 2018
36. RIVERA-DEL VALLE N, Cheng T, Irwin ME, Donnella H, et al
    Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Cancer Chemother Pharmacol. 2018;81:483-495.
    PubMed     Abstract available
    
    
    
37. BLOTNER S, Chen LC, Ferlini C, Zhi J, et al
    Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
    Cancer Chemother Pharmacol. 2018;81:597-607.
    PubMed     Abstract available
    
    
    
38. GERBEK T, Ebbesen M, Nersting J, Frandsen TL, et al
    Role of TPMT and ITPA variants in mercaptopurine disposition.
    Cancer Chemother Pharmacol. 2018;81:579-586.
    PubMed     Abstract available
    
    
    February 2018
39. SCHOCH LK, Asiama A, Zahurak M, Shanbhag S, et al
    Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.
    Cancer Chemother Pharmacol. 2018;81:347-354.
    PubMed     Abstract available
    
    
    January 2018
40. KIM SY, Park JH, Yoon SY, Cho YH, et al
    A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2018 Jan 2. pii: 10.1007/s00280-017-3514.
    PubMed     Abstract available
    
    
    
41. NIKANJAM M, Capparelli EV, Lancet JE, Louie A, et al
    Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Cancer Chemother Pharmacol. 2018;81:171-178.
    PubMed     Abstract available
    
    
    December 2017
42. VOLLER S, Pichlmeier U, Zens A, Hempel G, et al
    Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2017 Dec 5. pii: 10.1007/s00280-017-3492.
    PubMed     Abstract available
    
    
    November 2017
43. EMADI A, Law JY, Strovel ET, Lapidus RG, et al
    Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2017 Nov 8. doi: 10.1007/s00280-017-3459.
    PubMed     Abstract available
    
    
    October 2017
44. MCATEE CL, Schneller N, Brackett J, Bernhardt MB, et al
    Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification.
    Cancer Chemother Pharmacol. 2017 Oct 19. doi: 10.1007/s00280-017-3453.
    PubMed     Abstract available
    
    
    August 2017
45. BEN HASSINE I, Gharbi H, Soltani I, Ben Hadj Othman H, et al
    Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Cancer Chemother Pharmacol. 2017 Aug 23. doi: 10.1007/s00280-017-3424.
    PubMed     Abstract available
    
    
    June 2017
46. DEHGHAN-NAYERI N, Eshghi P, Pour KG, Rezaei-Tavirani M, et al
    Differential expression pattern of protein markers for predicting chemosensitivity of dexamethasone-based chemotherapy of B cell acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2017 Jun 5. doi: 10.1007/s00280-017-3347.
    PubMed     Abstract available
    
    
    May 2017
47. MESRIAN TANHA H, Rahgozar S, Mojtabavi Naeini M
    ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2017 May 26. doi: 10.1007/s00280-017-3340.
    PubMed     Abstract available
    
    
    March 2017
48. LANVERS-KAMINSKY C
    Asparaginase pharmacology: challenges still to be faced.
    Cancer Chemother Pharmacol. 2017;79:439-450.
    PubMed     Abstract available
    
    
    
49. YE YE, Woodward CN, Narasimhan NI
    Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans.
    Cancer Chemother Pharmacol. 2017;79:507-518.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: